Publication Name	World Journal of Gastroenterology
Manuscript ID	17927
Country	China

Received	2015-03-30 09:00
Peer-Review Started	2015-03-31 08:46
To Make the First Decision	2015-04-23 13:14
Return for Revision	2015-04-30 16:48
Revised	2015-05-15 09:55
Second Decision	2015-07-03 20:55
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-07-09 10:55
Articles in Press	2015-07-09 10:55
Publication Fee Transferred
Edit the Manuscript by Language Editor	2015-07-17 00:43
Typeset the Manuscript	2015-08-13 15:06
Publish the Manuscript Online	2015-08-28 17:04

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Basic Study
Article Title	Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway
Manuscript Source	Unsolicited Manuscript
All Author List	Qian Ding, Xiang-Guo Tian, Yan Li, Qi-Zhi Wang and Chun-Qing Zhang
Funding Agency and Grant Number	Funding Agency Grant Number National Natural Science Foundation of China 81370590
Corresponding Author	Chun-Qing Zhang, PhD, Department of Gastroenterology, Provincial Hospital Affiliated to Shandong University, 324 Jingwu Weiqi Road, Jinan 250021, Shandong Province, China. zhchqing@medmail.com.cn
Key Words	Carvedilol; Adrenergic β-antagonists; Angiogenesis; Liver cirrhosis; Drug utilization
Core Tip	Carvedilol has been used for the treatment of portal hypertension for many years. In this study, carvedilol directly inhibited the proliferation and tube formation of cultured human umbilical vascular endothelial cells. Moreover, this study is the first to investigate the mechanism of the anti-angiogenic effect of carvedilol, which functions by inhibiting vascular endothelial growth factor-induced mitogen-activated protein kinase signaling pathways. These novel activities of carvedilol provide insight into the anti-angiogenic mechanisms involved, and highlight its potential therapeutic application against angiogenesis-dependent liver fibrosis.
Publish Date	2015-08-28 17:04
Citation	Ding Q, Tian XG, Li Y, Wang QZ, Zhang CQ. Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway. World J Gastroenterol 2015; 21(32): 9566-9576
URL	http://www.wjgnet.com/1007-9327/full/v21/i32/9566.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i32.9566

Full Article (PDF)	WJG-21-9566.pdf
Full Article (Word)	WJG-21-9566.doc
Manuscript File	17927-Review.docx
Answering Reviewers	17927-Answering reviewers.pdf
Audio Core Tip	17927-Audio core tip.mp3
Biostatistics Review Certificate	17927-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	17927-Conflict-of-interest statement.pdf
Copyright License Agreement	17927-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	17927-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	17927-Language certificate.pdf
Peer-review Report	17927-Peer-review(s).pdf
Scientific Misconduct Check	17927-Scientific misconduct check.pdf
Scientific Editor Work List	17927-Scientific editor work list.pdf